CytoFab (BTG/AstraZeneca) fails Sepsis trial - 09-Aug-2012

BTG disclosed top-line results from a Phase IIb study conducted by AstraZeneca which had compared two doses of CytoFab (polyclonal ovine anti-TNF antibody fragments) with a placebo in patients with severeSepsis and/or Septic Shock. Treatment with CytoFab failed to show any significant improvements versus placebo with regard to either the primary endpoint of ventilator-free days or secondary endpoints such as mortality. AstraZeneca has withdrawn from the collaboration with BTG